Radicava Is The New Drug Approved By The FDA To Treat ALS

 After nearly two decades, the FDA approves a drug that aims at treating the paralyzing condition known as Lou Gehrig’s disease. The disease affects between 12,000 to 15,000 Americans, and is characterized by paralysis of the muscles, which can eventually lead to death. The study was conducted in Japan with 137 patients who were randomly selected to either taking Radicava or placebo. Those patients who took Radicava showed less severe symptoms compared to those in the placebo.

Relevance to Marketing

In chapter 9, we discussed the topic of new product development and the phases a product goes through in the market. As a new product, Radicava is probably in the very first phase, which is market introduction. In this phase, sales are not as high because people are still gaining familiarity with the product. The next phases Radicava will probably experience will be market growth followed by market maturity and sales decline.

Priscila Quimboca

MKTG 3343

Article: https://www.wsj.com/articles/fda-approves-first-als-drug-in-over-two-decades-1494026014?mod=nwsrl_health

Image: https://www.google.com/search?q=FDA&source=lnms&tbm=isch&sa=X&ved=0ahUKEwiT-bnU99vTAhUlxYMKHXJkCBgQ_AUIBygC&biw=1366&bih=694#imgrc=YaXt8RBDfIjhnM: